A basic research to develop cancer peptide vaccine for transdermal immunization

• Project/Area Number: 17K07229
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Tumor therapeutics
• Research Institution: Kurume University
• Principal Investigator: Waki Kayoko 久留米大学, 付置研究所, 助教 (40649597)
• Co-Investigator(Kenkyū-buntansha): 山田 亮 久留米大学, 付置研究所, 教授 (50158177)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Project Status: Completed (Fiscal Year 2019)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: がんペプチドワクチン / 経皮ワクチン / 癌 / 腫瘍免疫 / ペプチドワクチン

Outline of Final Research Achievements

This project aimed to develop transdermal cancer peptide vaccine without Floyd’s incomplete adjuvant using a mouse model. Lactic acid-based chemical peeling prior to peptide vaccination augmented the proliferation of peptide-specific T cells in the CFSE cell division assay. In addition, application of imiquimod cream at the vaccinated site following the vaccination significantly induced peptide specific cytotoxic T cells in IFN-gamma ELISPOT assay. These suggested the possibility of transdermal cancer peptide vaccine, which was patient-friendly.

Academic Significance and Societal Importance of the Research Achievements

がんペプチドワクチンはがん抗原ペプチドをフロイント不完全アジュバントでエマルジョン化したワクチンを皮下投与するのが主流であるが、ワクチンの投与部位への長期残留と炎症反応が患者の大きな負担になっている。本研究で行った乳酸を用いた経皮がんペプチドワクチンが抗原特異的細胞傷害性T細胞を誘導できることから、患者にやさしい経皮がんペプチドワクチン療法の可能性を示唆している。

Research Products

• [Journal Article] Immunological efficacy of herbal medicines in prostate cancer patients treated by personalized peptide vaccine (2017)
  • Author(s): Koga Noriko、Moriya Fukuko、Waki Kayoko、Yamada Akira、Itoh Kyogo、Noguchi Masanori
  • Journal Title: Cancer Science Volume: 108 Issue: 12 Pages: 2326-2332
  • DOI: 10.1111/cas.13397
  • Peer Reviewed / Open Access
• [Journal Article] Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies (2017)
  • Author(s): Yutani Shigeru、Shirahama Takahisa、Muroya Daisuke、Matsueda Satoko、Yamaguchi Rin、Morita Michi、Shichijo Shigeki、Yamada Akira、Sasada Tetsuro、Itoh Kyogo
  • Journal Title: Cancer Science Volume: 108 Issue: 9 Pages: 1732-1738
  • DOI: 10.1111/cas.13301
  • Peer Reviewed / Open Access
• [Journal Article] Feasibility Study of Personalized Peptide Vaccination for Advanced Small Cell Lung Cancer. (2017)
  • Author(s): Sakamoto S, Yamada T, Terazaki Y, Yoshiyama K, Sugawara S, Takamori S, Matsueda S, Shichijo S, Yamada A, Noguchi M, Itoh K, Hattori N, Kohno N, Sasada T.
  • Journal Title: Clin Lung Cancer. Volume: 印刷中 Issue: 6 Pages: e385-e394
  • DOI: 10.1016/j.cllc.2017.03.011
  • Peer Reviewed / Open Access
• [Journal Article] Plasma Levels of High-Mobility Group Box 1 during Peptide Vaccination in Patients with Recurrent Ovarian Cancer. (2017)
  • Author(s): Waki K, Kawano K, Tsuda N, Ushijima K, Itoh K, Yamada A.
  • Journal Title: Journal of Immunology Research Volume: 2017 Pages: 1423683-1423683
  • DOI: 10.1155/2017/1423683
  • Peer Reviewed / Open Access
• [Journal Article] A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer. (2017)
  • Author(s): Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S.
  • Journal Title: Cancer Sci. Volume: 印刷中 Issue: 5 Pages: 838-845
  • DOI: 10.1111/cas.13193
  • Peer Reviewed / Open Access
• [Journal Article] Immunological evaluation of peptide vaccination for cancer patients with the HLA -A11+ or -A33+ allele. (2017)
  • Author(s): Sakamoto S, Matsueda S, Takamori S, Toh U, Noguchi M, Yutani S, Yamada A, Shichijo S, Yamada T, Suekane S, Kawano K, Naitou M, Sasada T, Hattori N, Kohno N, Itoh K.
  • Journal Title: Cancer Sci. Volume: 印刷中 Issue: 4 Pages: 598-603
  • DOI: 10.1111/cas.13189
  • Peer Reviewed / Open Access
• [Presentation] Plasma cell-free DNA integrity and the prognosis in the advanced endometrial cancer patients with peptide vaccination (2019)
  • Author(s): 和氣加容子
  • Organizer: 第７８回日本癌学会学術総会
• [Presentation] 末梢血セルフリーDNA integrityはペプチドワクチン療法において有用なバイオマーカーとなりうる：非小細胞肺がんでの解析 (2018)
  • Author(s): 和氣加容子、山田亮
  • Organizer: 第22回日本がん免疫学会総会
• [Presentation] Plasma cell-free DNA integrity analyses for ovarian and non-small cell lung cancer patients with peptide vaccination (2018)
  • Author(s): 和氣加容子、山田亮
  • Organizer: 第77回日本癌学会学術総会
• [Presentation] 古典的Ｔ細胞サブセットCD4、CD8(末梢血中)の変動はペプチドワクチン療法の優れた予後予測因子となりうる：進行・再発卵巣がんでの解析 (2017)
  • Author(s): 和氣加容子
  • Organizer: 第21回日本がん免疫学会総会
• [Presentation] Integrity of cell-free DNA in plasma as a useful biomarker for responses to peptide vaccine in ovarian cancer patients (2017)
  • Author(s): 和氣加容子
  • Organizer: 第76回日本癌学会学術総会